WO2001058835A1 - Resolution of dl-racemic mixtures - Google Patents
Resolution of dl-racemic mixtures Download PDFInfo
- Publication number
- WO2001058835A1 WO2001058835A1 PCT/EP2000/001112 EP0001112W WO0158835A1 WO 2001058835 A1 WO2001058835 A1 WO 2001058835A1 EP 0001112 W EP0001112 W EP 0001112W WO 0158835 A1 WO0158835 A1 WO 0158835A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- enantiomer
- process according
- compound
- crystallization
- hydrochloride
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B57/00—Separation of optically-active compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
- C07C201/06—Preparation of nitro compounds
- C07C201/16—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/30—Preparation of optical isomers
- C07C227/34—Preparation of optical isomers by separation of optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/16—Preparation of optical isomers
- C07C231/20—Preparation of optical isomers by separation of optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/26—Separation; Purification; Stabilisation; Use of additives
- C07C319/28—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- the present invention relates to a process for the resolution DL-racemic mixtures of chiral compounds which crystallize in the form of any conglomerate and some DL-racemic systems which exhibit various kinds of crystal twinning, such as microtwinning, lamellar macrotwinning as well as DL-racemic mixtures having different crystalline polymorphs, enabling the recovery of both the D and the L enantiomers.
- the invention further provides an industrially feasible process for the optical resolution of such DL-racemates for continuously isolating both the D and L enantiomers.
- a DL-racemic compound is reacted with an optically active reagent (resolving agent) to form a mixture of diastereoisomeric derivatives, e.g. by salt formation, which can be separated e.g. by fractional crystallization.
- an optically active reagent resolving agent
- Each of the thus isolated diastereoisomeric derivatives can then be decomposed to obtain the desired enantiomer of the initial DL-racemic compound.
- the L-enantiomer of most of the amino acids can be isolated from their racemic N-acetyl-DL-amino acid racemic mixtures by enantiosel- ective hydrolysis of the N-acetyl-L-enantiomer using acylase I enzyme to afford the optically pure L-enantiomer.
- L- or D- PGAH Poly-[L- or D- -glutamyl (N-acryloyl hydra- zide)] L- or D- PA-Phe Poly-(p-acrylamido L-or D-phenyl-alanine) L- or D- PA-PAB-PHA Poly-[N-acryloyl-( ⁇ -aminobenzoyl)-L- or
- the L- or D- enantiomer of the amino acid bound to the polymer will be chosen according to the L- or D- enantiomer, respectively, the crystallization of which is to be inhibited.
- U.S. patent no. 4,864,031 also discloses a resolution method for the simultaneous recovery of both the D and L enantiomers where the DL-racemate is provided in two adjacent compartments of a resolution cell, separated by a suitable membrane which is permeable to the D- and L- enantiomers, but impermeable to the chiral polymeric inhibitor.
- the result is that in the first compartment an essentially pure L- enantiomer is crystallized and in the other - an essentially pure D- enantiomer. This process was found to be too time consuming for industrial application, because of the low rates of passage of the solutions between the compartments, through the membrane due to the considerably small concentration differentials between the enantiomers in each compartment.
- the invention in a first aspect thereof, provides a process for the resolution of a DL-racemic mixture of a compound crystallizing in the form of a conglomerate from a supersaturated solution thereof, to recover both the D and the L enantiomers, which process comprises the steps of: a) effecting a preferential crystallization of one of said enantiomers from said supersaturated solution in the presence of an effective amount of a chiral enantioselective polymer which inhibits the crystallization of the opposite enantiomer; b) physically separating the thus crystallized said one enantiomer to obtain a mother liquor comprising an excess of said opposite enantiomer; c) adding to said mother liquor solid DL-racemic mixture of said compound in about twice the amount of said one enantiomer separated in step (b) and stirring the resulting suspension at a suitable temperature until substantially the entire suspended solid phase consists of said opposite enantiomer; and d) physically separating said solid opposite en
- the invention provides a continuous process for the resolution of DL-racemic mixture of a compound crystallizing in the form of a conglomerate from a supersaturated solution thereof, to recover both the D and the L enantiomers, the process comprising a plurality of cycles of steps a) to d) as described above wherein the supersaturated solution obtained in step d) of each cycle is submitted to the preferential crystallization in step a) of the next cycle and said cycle is repeated ad lib.
- the first step (a) of the resolution process of the invention is conducted in the same manner as described in U.S. 4,864,031, using the same chiral polymeric additives which enantioselectively inhibit the nucleation and growth of crystals of the enantiomer having the same chirality, without affecting the opposite enantiomer.
- the amounts of the chiral polymer that should be added in order to reach the desired result range between about 1 to 3% by weight of the DL-racemic mixture in the solution. Separation of the precipitated enantiomer, e.g. by filtration, in step (b) affords this product at high chemical and optical yields.
- the use of seed crystals of the enantiomer to be precipitated in this step is not required, but may, however, be desirable from the point of view of the rate of crystallization.
- the opposite enantiomer can be successfully recovered in the above step c) in high chemical and optical yields, from the mother liquor obtained in step b) after separation of the crystallized first enantiomer, without the need to remove the polymeric crystal growth inhibitor (for the opposite enantiomer) which is present in this mother liquor in substantially its initial concentration, since the polymer is not occluded in the crystals of the first polymer precipitated in step a).
- the opposite isomer is recovered in step c) by the addition to the mother liquor of solid DL-racemic mixture in about twice the amount of the first enantiomer isolated in step b) and stirring the resulting suspension at a suitable temperature, which is higher than the initial crystallization tempera- ture in process a), until the suspension reaches an equilibrium at which point it was found that substantially the entire suspended solid phase consists of the opposite enantiomer of high optical purity.
- the crystallized opposite enantiomer is then separated by physical means, e.g. filtration.
- step c) Any attempt to dissolve the added solid DL-racemic mixture in step c) by heating the solution so as to form a clear solution rather than a suspension, would make it almost impossible to induce the crystallization of the opposite enantiomer, even though it is present in the solution in excess, owing to the presence in the solution of the enantioselective polymer which inhibits the nucleation and crystallization of this opposite enantiomer. In such a case, even seeding with seed crystals of the opposite enantiomer is of no avail and, if anything crystallizes at all, it will be most probably the other non-inhibited enantiomer.
- step c) the suspension formed in step c) by the addition of the solid DL-racemic mixture to the mother liquor of step b), reaches an equilibrium after stirring for about 7 to 19 hours at the optimal temperature.
- This optimal temperature is the one at which the amount of the opposite enantiomer which can be separated as a solid from the suspension after the prolonged stirring is equal to the amount of the first enantiomer which crystallized in process step a). Separation of this solid opposite enantiomer leaves a solution having substantially the same composition as the original supersaturated solution of the DL-racemic mixture used in step a) and including substantially the initial amount of the polymeric crystal growth inhibitor which was present in the starting solution in step a).
- process step c) is carried out at a lower temperature than the aforesaid optimal temperature, the amount of the added solid going into the solution will be reduced and consequently the amount of the solid obtained is higher and contains more of the DL-racemic mixture, i.e. the optical purity is lower. Conversely, if process step c) is conducted at a higher temperature than the optimal one, a larger amount of the added solid will dissolve in the solution, leading to a solution which contains in excess the opposite enantiomer of the one crystallized in step a).
- the optimal initial crystallization temperature is dependent on the concentration of this hydrochloric acid solution.
- concentration of the hydrochloric acid in the aqueous solution the higher is the optimal temperature at which the crystallization of the desired enantiomer should be started and vice versa. This optimal temperature should thus be experimentally determined in each specific case where hydrochloric acid is used.
- the process of the invention has been successfully applied to DL-racemic systems which exhibit various kinds of crystal twinning, such as microtwinning, lamellar macrotwinning as well as DL-racemic mixtures having different crystalline polymorphs and even where the thermodynami- cally most favorable polymorph is the crystalline racemate which precipitates regardless of the type of crystals used for seeding.
- the mother liquor obtained in process step d) which, as stated above, has substantially the same composition as the starting solution subjected to preferential crystallization in process step a), can be submitted to an additional cycle of process ⁇ steps a) to d) which cycle can be repeated ad lib, thereby achieving continuous resolution of the DL-racemic mixture to recover the D- and the L- enantiomers at high chemical and optical yields.
- This continuous resolution process according to the invention has been achieved in a considerable number of various racemic mixtures which crystallize as conglomerates.
- DL-methionine hydrochloride DL-Met-HCl
- DL-glutamic acid hydrochloride DL-Glu-HC- 1
- DL-histidine hydrochloride monohydrate DL-His-HCl-H 2 0
- DL-asparagine monohydrate DL-Asn-EbO
- DL-Thr DL-threonine
- DL-Leu HCl DL-Leu HCl
- DL-valine hydrochloride DL-Val-HCl
- DL-Isoleu-HCL DL-cysteine hydrochloride
- DL-Cys-HCl DL-sec-phenethylalcohol-3,5-dinitrobenzoate.
- DL-Met-HCl was dissolved by heating and stirring in 105 ml of aqueous concentrated (32%) hydrochloric acid and the solution was cooled to room temperature.
- aqueous concentrated (32%) hydrochloric acid 0.9 g of poly-(N methacryloyl-D-lysine) (D-PMAL) was dissolved in 7.5 ml of water at room temperature and the resulting solution was added to the methionine hydrochloride solution.
- the HCl concentration in the resulting solution was about 22%.
- the combined clear solution was seeded with L-methionine hydrochloride seed crystals (3 mg) and placed in a thermostated cooling bath.
- the starting temperature of crystallization was 13°C which was decreased to 6°C at a rate of 0.5°C per hour for the first 2 hrs, and 1°C every further hour, down to 6°C.
- the solution was then left at 6°C for one hour.
- Mechanical stirring was started after 3-4 hrs from the start of the crystallization and continued regularly till the end of the crystallization process. (Alternatively, the stirring can start at the beginning of the crystallization without affecting the end result).
- the precipitated small needle-like crystals were filtered through a sintered glass filter (No. 1) and dried. 6.69 g (23.9%) of L-Met-HCl were obtained consisting of 97% L and 3% D (by chiral G.C. and H.P.L.C. analysis).
- a sample of the product was washed with 37% hydrochloric acid to obtain crystals consisting of 98.74% L- and 1.26% D-Met-HCl.
- Example 1(a) The mother liquor obtained in Example 1(a) above was recrystallized as described in that Example to afford 5.5 g of L-Met-HCl composed of 96% L and 4% D (by chiral G.C. and H.P.L.C. analysis).
- the above procedure was repeated for 18 more cycles and the L-Met-HCl and D-Met-HCl were collected separately.
- the amounts of solid powdered DL-Met-HCl added in each cycle to the mother liquor obtained after the filtration of the crystallized L-Met-HCl ranged between 2 to 2.7 times the amount of the L-Met-HCl recovered in the preceding step.
- Example 3 The procedure of Examples 1 and 2 was repeated except that the initial supersaturated solution included L-PMAL instead of D-PMAL. Therefore, D-Met-HCl crystallized in the first step (a) and the mother liquor obtained after the filtration of this product included an excess of L-Met-HCl, which could be recovered therefrom by the procedure of Example 1(b) above. Repeated cycles of these operations afforded the D- and L-Met-HCl in substantially the same amounts as given in Table II above.
- the L and D enantiomers were separated by the procedure of Example 1 in the following systems: Glu-HCl, His-HCl-H 2 0, Asn-H 2 0, Thr, Leu-HCl, Val-HCl, Isoleu-HCl, Cys-HCl and sec-phenethyl 3,5-dinitrobenzoate.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2000/001112 WO2001058835A1 (en) | 2000-02-11 | 2000-02-11 | Resolution of dl-racemic mixtures |
US10/181,411 US6673942B1 (en) | 2000-02-11 | 2000-02-11 | Resolution of DL-racemic mixtures |
ES00907546T ES2214254T3 (en) | 2000-02-11 | 2000-02-11 | RESOLUTION OF RACEMICAL BLENDS DL. |
DE60007901T DE60007901T2 (en) | 2000-02-11 | 2000-02-11 | SEPARATION OF DL-RACEMIC MIXTURES |
JP2001558389A JP2003522745A (en) | 2000-02-11 | 2000-02-11 | Resolution of DL-racemic mixture |
AT00907546T ATE258154T1 (en) | 2000-02-11 | 2000-02-11 | SEPARATION OF DL RACE MIXTURES |
EP00907546A EP1254092B1 (en) | 2000-02-11 | 2000-02-11 | Resolution of dl-racemic mixtures |
PT00907546T PT1254092E (en) | 2000-02-11 | 2000-02-11 | DL RACEMIC MIXTURES RESOLUTION |
DK00907546T DK1254092T3 (en) | 2000-02-11 | 2000-02-11 | Resolution of DL racemic mixtures |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2000/001112 WO2001058835A1 (en) | 2000-02-11 | 2000-02-11 | Resolution of dl-racemic mixtures |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001058835A1 true WO2001058835A1 (en) | 2001-08-16 |
Family
ID=8163830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/001112 WO2001058835A1 (en) | 2000-02-11 | 2000-02-11 | Resolution of dl-racemic mixtures |
Country Status (9)
Country | Link |
---|---|
US (1) | US6673942B1 (en) |
EP (1) | EP1254092B1 (en) |
JP (1) | JP2003522745A (en) |
AT (1) | ATE258154T1 (en) |
DE (1) | DE60007901T2 (en) |
DK (1) | DK1254092T3 (en) |
ES (1) | ES2214254T3 (en) |
PT (1) | PT1254092E (en) |
WO (1) | WO2001058835A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005009999A1 (en) * | 2003-07-29 | 2005-02-03 | Dainippon Sumitomo Pharma Co., Ltd. | Process for producing imide compound |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1656454A4 (en) * | 2003-07-08 | 2011-06-22 | Novus Int Inc | Methionine recovery processes |
GB201417644D0 (en) * | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0225503A1 (en) * | 1985-11-12 | 1987-06-16 | Yeda Research And Development Company Limited | Resolution system |
-
2000
- 2000-02-11 DK DK00907546T patent/DK1254092T3/en active
- 2000-02-11 PT PT00907546T patent/PT1254092E/en unknown
- 2000-02-11 ES ES00907546T patent/ES2214254T3/en not_active Expired - Lifetime
- 2000-02-11 DE DE60007901T patent/DE60007901T2/en not_active Expired - Lifetime
- 2000-02-11 JP JP2001558389A patent/JP2003522745A/en active Pending
- 2000-02-11 US US10/181,411 patent/US6673942B1/en not_active Expired - Fee Related
- 2000-02-11 EP EP00907546A patent/EP1254092B1/en not_active Expired - Lifetime
- 2000-02-11 WO PCT/EP2000/001112 patent/WO2001058835A1/en active IP Right Grant
- 2000-02-11 AT AT00907546T patent/ATE258154T1/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0225503A1 (en) * | 1985-11-12 | 1987-06-16 | Yeda Research And Development Company Limited | Resolution system |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005009999A1 (en) * | 2003-07-29 | 2005-02-03 | Dainippon Sumitomo Pharma Co., Ltd. | Process for producing imide compound |
JPWO2005009999A1 (en) * | 2003-07-29 | 2006-09-07 | 大日本住友製薬株式会社 | Method for producing imide compound |
AU2004259305B2 (en) * | 2003-07-29 | 2009-06-04 | Sumitomo Pharma Co., Ltd. | Process for producing imide compound |
US7605260B2 (en) | 2003-07-29 | 2009-10-20 | Dainippon Sumitomo Pharma Co., Ltd. | Process for producing imide compound |
USRE45573E1 (en) | 2003-07-29 | 2015-06-23 | Sumitomo Dainippon Pharma Co., Ltd. | Process for producing imide compound |
Also Published As
Publication number | Publication date |
---|---|
US6673942B1 (en) | 2004-01-06 |
EP1254092B1 (en) | 2004-01-21 |
DE60007901D1 (en) | 2004-02-26 |
ATE258154T1 (en) | 2004-02-15 |
DK1254092T3 (en) | 2004-03-15 |
PT1254092E (en) | 2004-06-30 |
EP1254092A1 (en) | 2002-11-06 |
JP2003522745A (en) | 2003-07-29 |
DE60007901T2 (en) | 2004-10-28 |
ES2214254T3 (en) | 2004-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101699095B1 (en) | Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid | |
EP1034826A1 (en) | Co-crystallization process | |
US3405159A (en) | Process for resolving racemic mixtures of optically-active enantiomorphs | |
US6015903A (en) | Method of resolving racemic mixtures | |
HU212703B (en) | Process for producing optically active amino acid amide | |
US4914208A (en) | Optically active salts of a substituted thiazolidine-4-carboxylate and 3-chloro-2-hydroxypropyltrimethyl ammonium, their preparation and use | |
EP2681186B1 (en) | Process of resolution of 1-aminoindan | |
EP1254092B1 (en) | Resolution of dl-racemic mixtures | |
EP0499376A1 (en) | Precipitation-induced asymmetric transformation of chiral alpha-amino acids and salts thereof | |
EP1330450B1 (en) | Process for the production of r(+)alpha-lipoic acid | |
US4533506A (en) | Resolution of amino acids | |
EP1912931A2 (en) | Preparation of (s)-pregabalin-nitrile | |
US4625054A (en) | Process for the resolution of (+)-6-methoxy-α-methyl-2-naphthaleneacetic acid into the corresponding enantiomers | |
IL122633A (en) | Kinetic resolution of dl-racemic mixtures by polymer-bound crystallization inhibitors | |
US4642205A (en) | Diastereomer salts of phenylalanine and N-acyl derivatives thereof and process for the separation of optically active phenylalanine and N-acyl derivatives thereof | |
EP0253571B1 (en) | Process for resolution and race mization of amines with acidic alpha-hydrogens | |
US20050065367A1 (en) | Method for producing optically active beta-phenylalanine | |
US4285884A (en) | Process for resolution of racemic DL-α-aminocarboxylic acids | |
HU205594B (en) | Process for producing optical isomeres of cyclopropane-carboxylic acids5 | |
RU2245868C2 (en) | Method of separating racemic 1-(isopropylamino)-3-(1-naphthyloxy)-2-propanol into enantiomers | |
US5367091A (en) | Optical resolution of DL-3-acetylthio-2-methylpropionic acid using L-(+)-2-aminobutanol as resolving agent | |
US6172259B1 (en) | Production of enantiomer-free biarylketocarboxylic acids | |
HU212704B (en) | Process for racemization of optically active amino acid amide | |
JPS641459B2 (en) | ||
JPH0470306B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000907546 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10181411 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 558389 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2000907546 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000907546 Country of ref document: EP |